Publications
Publications
Show Results For
- All HBS Web
(120,116)
- Faculty Publications (39)
←
Page 2 of 39
Results
- August 2022
- Case
In-Q-Tel: Innovation On A Mission
By: Joshua Lev Krieger and Josh Lerner
In 2022, the leaders of In-Q-Tel (IQT) considered what was next for the unique mission-driven organization. Since 1999, IQT had one mission: to be the most sophisticated source of strategic technical knowledge and capabilities to the U.S. government and its allies. IQT... View Details
- March 2022
- Teaching Note
Tomorrow.io Goes To Space
By: Joshua Lev Krieger, Abhishek Nagaraj and James Barnett
Teaching Note for HBS Case No. 822-005. In March 2021, the weather company Tomorrow.io announced a new project to develop satellites equipped with radar for weather monitoring and launch them into Earth’s orbit. Company leadership considers execution strategies. View Details
- March 2022
- Teaching Note
Biobot Analytics
- 2022
- Article
Missing Novelty in Drug Development
By: Joshua Krieger, Danielle Li and Dimitris Papanikolaou
We provide evidence that risk aversion leads pharmaceutical firms to underinvest in radical innovation. We introduce a new measure of drug novelty based on chemical similarity and show that firms face a risk-reward trade-off: novel drug candidates are less likely to... View Details
- January 2022
- Case
Tomorrow.io Goes to Space
By: Joshua Lev Krieger, Abhishek Nagaraj and James Barnett
This case study explores the evolution of Tomorrow.io, a weather forecasting technology company, as it pivoted toward building and launching space-based weather radar satellites. This strategic shift was driven by the company's ambition to overcome data limitations in... View Details
- January 2022 (Revised March 2022)
- Teaching Note
Catalys Pacific
Teaching Note for HBS Case No. 821-035. View Details
- November 2021 (Revised March 2022)
- Case
AppHarvest: Rebuilding the Appalachian Economy Through Agriculture
By: Joshua Lev Krieger, William R. Kerr and Christian Godwin
In 2021, AppHarvest completed construction of a 60-acre indoor farming facility, one of the world’s largest, recorded its first sales, and went public in a multi-billion dollar IPO. Described as “a force of nature,” Jonathan Webb founded the company to bring jobs back... View Details
- September 2021
- Article
Trials and Terminations: Learning from Competitors' R&D Failures
I analyze project continuation decisions where firms may resolve uncertainty through news about competitors' research and development (R&D) failures, as well as through their own results. I examine the trade-offs and interactions between product-market competition and... View Details
- May 2021
- Article
Private and Social Returns to R&D: Drug Development and Demographics
By: Efraim Benmelech, Janice Eberly, Dimitris Papanikolaou and Joshua Krieger
Investment in intangible capital such as R&D has increased dramatically since the 1990s. However, productivity growth remains sluggish in recent years. One potential reason is that a significant share of the increase in intangible investment is geared toward consumer... View Details
- January 2021 (Revised June 2023)
- Case
Biobot Analytics
In 2017, Newsha Ghaeli and Mariana Matus were deciding whether to leave their labs at the Massachusetts Institute of Technology, put other job opportunities aside, and dive full-time into founding a wastewater analysis start-up, Biobot. Ghaeli, an architect, and Matus,... View Details
- December 2020 (Revised March 2022)
- Teaching Note
Forecasting ClimaCell
By: Joshua Lev Krieger, Christopher Stanton and James Barnett
A weather technology startup, ClimaCell considers the R&D trade-offs and financing implications of pursuing a proposed contract with a major automobile maker, rather than continuing its focus on building a scalable, all-purpose weather prediction engine. View Details
- September 2020 (Revised January 2021)
- Case
Catalys Pacific
In 2019, BT Slingsby founds Catalys Pacific, the first biotech “venture creation” fund in Tokyo. After convincing some of the biggest Japanese pharmaceutical firms to invest, BT hopes the fund can make a big splash and transform biotechnology innovation in Japan. After... View Details
Keywords: Pharmaceutical Companies; Biotech; Health Care; Entrepreneur; Innovation; International Business; Entrepreneurial Finance; Entrepreneurship; Finance; Innovation Strategy; Venture Capital; Strategy; Cross-Cultural and Cross-Border Issues; Pharmaceutical Industry; Biotechnology Industry; Tokyo
- December 2019
- Case
Forecasting ClimaCell
By: Joshua Lev Krieger, Christopher Stanton and James Barnett
A weather technology startup, ClimaCell considers the R&D trade-offs and financing implications of pursuing a proposed contract with a major automobile maker, rather than continuing its focus on building a scalable, all-purpose weather prediction engine. View Details
- November 2017
- Case
The 'Wonder Drug' That Killed Babies
By: Joshua Lev Krieger, Tom Nicholas and Matthew Preble
In the early 1960s, a popular drug taken by patients worldwide for a range of maladies was found to cause severe birth defects and other health problems in babies born to mothers who had taken it during a certain stage of fetal development. As many as 10,000 children... View Details
Keywords: Regulation; Business and Government Relations; Business and Community Relations; Business and Stakeholder Relations; Product Marketing; Corporate Social Responsibility and Impact; Business History; Health; Government Legislation; Corporate Accountability; Ethics; Governing Rules, Regulations, and Reforms; Pharmaceutical Industry; Public Administration Industry; United States; United Kingdom; Australia; Germany; Europe
- Article
The Career Effects of Scandal: Evidence from Scientific Retractions
By: Pierre Azoulay, Alessandro Bonatti and Joshua Lev Krieger
We investigate how the scientific community's perception of a scientist's prior work changes when one of his articles is retracted. Relative to non-retracted control authors, faculty members who experience a retraction see the citation rate to their earlier,... View Details
- Article
The Impact of Personal Genomics on Risk Perceptions and Medical Decision-Making
By: Joshua Lev Krieger, Fiona Murray, J. Scott Roberts and Robert C. Green
- Forthcoming
- Article
How Important Is Editorial Gatekeeping? Evidence from Top Biomedical Journals
By: Joshua L. Krieger, Kyle R. Myers and Ariel D. Stern
We examine editors' influence on the scientific content of academic journals by unpacking the role of three major forces: journals' missions, aggregate supply of and demand for specific topics, and scientific homophily via editorial gatekeeping. In a sample of top... View Details
- Research Summary
Overview
In examining the competitive dynamics of R&D strategy, Josh has become particularly interested in how the introduction of new knowledge generated by rivals impacts the direction of R&D efforts. Understanding how new information alters project portfolio decisions is... View Details